317 related articles for article (PubMed ID: 2185906)
1. Clinical pharmacokinetics of imipramine and desipramine.
Sallee FR; Pollock BG
Clin Pharmacokinet; 1990 May; 18(5):346-64. PubMed ID: 2185906
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers.
Ciraulo DA; Barnhill JG; Jaffe JH
Clin Pharmacol Ther; 1988 May; 43(5):509-18. PubMed ID: 3365915
[TBL] [Abstract][Full Text] [Related]
3. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.
Brøsen K; Gram LF
Clin Pharmacol Ther; 1988 Apr; 43(4):400-6. PubMed ID: 3356084
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic correlation between in vitro hepatic microsomal enzyme kinetics and in vivo metabolism of imipramine and desipramine in rats.
Chiba M; Fujita S; Suzuki T
J Pharm Sci; 1990 Apr; 79(4):281-7. PubMed ID: 2352136
[TBL] [Abstract][Full Text] [Related]
5. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine.
Brøsen K; Gram LF
Eur J Clin Pharmacol; 1989; 37(2):155-60. PubMed ID: 2792169
[TBL] [Abstract][Full Text] [Related]
6. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction.
Bergstrom RF; Peyton AL; Lemberger L
Clin Pharmacol Ther; 1992 Mar; 51(3):239-48. PubMed ID: 1544284
[TBL] [Abstract][Full Text] [Related]
7. Regional distribution of imipramine, desipramine and specific [3H]desipramine binding sites in the rat brain after acute and chronic treatment with imipramine.
Daniel W; Danek L; Janczar L; Nocon H; Melzacka M
J Pharm Pharmacol; 1991 Jan; 43(1):31-5. PubMed ID: 1676056
[TBL] [Abstract][Full Text] [Related]
8. The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine.
Nguyen HQ; Callegari E; Obach RS
Drug Metab Dispos; 2016 Oct; 44(10):1569-78. PubMed ID: 27440861
[TBL] [Abstract][Full Text] [Related]
9. Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine.
Hermann DJ; Krol TF; Dukes GE; Hussey EK; Danis M; Han YH; Powell JR; Hak LJ
J Clin Pharmacol; 1992 Feb; 32(2):176-83. PubMed ID: 1613128
[TBL] [Abstract][Full Text] [Related]
10. Imipramine and desipramine disposition in the elderly.
Abernethy DR; Greenblatt DJ; Shader RI
J Pharmacol Exp Ther; 1985 Jan; 232(1):183-8. PubMed ID: 3965690
[TBL] [Abstract][Full Text] [Related]
11. Stable isotope coadministration methodology for the estimation of the fraction of imipramine metabolized to desipramine.
Sasaki Y; Shinohara Y; Baba S
J Pharm Sci; 1990 Feb; 79(2):96-8. PubMed ID: 2324970
[TBL] [Abstract][Full Text] [Related]
12. The effect of sertraline on the pharmacokinetics of desipramine and imipramine.
Kurtz DL; Bergstrom RF; Goldberg MJ; Cerimele BJ
Clin Pharmacol Ther; 1997 Aug; 62(2):145-56. PubMed ID: 9284850
[TBL] [Abstract][Full Text] [Related]
13. Plasma levels of imipramine and metabolites in 68 hospitalized children.
Preskorn SH; Bupp SJ; Weller EB; Weller RA
J Am Acad Child Adolesc Psychiatry; 1989 May; 28(3):373-5. PubMed ID: 2738003
[TBL] [Abstract][Full Text] [Related]
14. Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects.
Spina E; Avenoso A; Campo GM; Scordo MG; Caputi AP; Perucca E
Br J Clin Pharmacol; 1997 Mar; 43(3):315-8. PubMed ID: 9088587
[TBL] [Abstract][Full Text] [Related]
15. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects.
Spina E; Pollicino AM; Avenoso A; Campo GM; Perucca E; Caputi AP
Ther Drug Monit; 1993 Jun; 15(3):243-6. PubMed ID: 8333005
[TBL] [Abstract][Full Text] [Related]
16. Imipramine metabolites in blood of patients during therapy and after overdose.
Gram LF; Bjerre M; Kragh-Sørensen P; Kvinesdal B; Molin J; Pedersen OL; Reisby N
Clin Pharmacol Ther; 1983 Mar; 33(3):335-42. PubMed ID: 6825388
[TBL] [Abstract][Full Text] [Related]
17. Steady-state kinetics of imipramine in transgenic mice with elevated serum AAG levels.
Holladay JW; Dewey MJ; Yoo SD
Pharm Res; 1996 Sep; 13(9):1313-6. PubMed ID: 8893267
[TBL] [Abstract][Full Text] [Related]
18. Imipramine: a model substance in pharmacokinetic research.
Gram LF
Acta Psychiatr Scand Suppl; 1988; 345():81-4. PubMed ID: 3067542
[TBL] [Abstract][Full Text] [Related]
19. Plasma concentration monitoring of hydroxylated metabolites of imipramine and desipramine.
DeVane CL; Jusko WJ
Drug Intell Clin Pharm; 1981 Apr; 15(4):263-6. PubMed ID: 7274042
[TBL] [Abstract][Full Text] [Related]
20. A comparative study on desipramine pharmacokinetics in the rat brain after administration of desipramine or imipramine.
Daniel W; Melzacka M
J Pharm Pharmacol; 1992 May; 44(5):429-32. PubMed ID: 1359059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
